Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case

Bevacizumab is a monoclonal antibody which is targeting to vascular endothelial growth factor. It has been shown to be a promising drug on metastatic colorectal cancer and is combined with chemotherapeutic agents. One should be aware of serious complications even though bevacizumab is a well-tolerated drug. There are a few in­testinal perforation cases that have been reported in the oncologic surgery literature related to the bevacizumab treatment. In this case report, we aimed to represent a 45 years old man who was diagnosed with intestinal per­foration after bevacizumab treatment ten months after a metastatic colon cancer surgery